Wave aims for monthly dosing with RNA editing treatment for AATD

Wave Life Sciences reported an updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin deficiency, suggesting that it can dose its genetic therapy monthly. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and…

Source: Endpoints News